Physical characterization of lansoprazole/PVP solid dispersion prepared by fluid-bed coating technique

Powder Technology

Volumn 182, Issue 3, 2008, Pages 480-485

  Zhang, Xingwang ^a,b   Sun, Ningyun ^a   Wu, Baojian ^a   Lu, Yi ^a   Guan, Tianzheng ^b   Wu, Wei ^a  

^a FUDAN UNIVERSITY   (China)

^b HENAN UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Fluid bed; Lansoprazole; Pellets; Physical characterization; Polyvinylpyrrolidone; Solid dispersion; Solubilization

Indexed keywords

COATING TECHNIQUES; DECOMPOSITION; PHOSPHATES; SOLUBILITY;

LANSOPRAZOLE; POLYVINYLPYRROLIDONE; SOLID DISPERSION;

DISPERSIONS;

BUFFER; LANSOPRAZOLE; PHOSPHATE; POVIDONE;

COATING TECHNIQUES; DECOMPOSITION; DISPERSIONS; PHOSPHATES; SOLUBILITY;

ARTICLE; CRYSTAL STRUCTURE; DECOMPOSITION; DISPERSION; DRUG COATING; DRUG CONFORMATION; DRUG SOLUBILITY; FLUIDIZED BED; FOURIER ANALYSIS; HYDROGEN BOND; MELTING POINT; PH; X RAY DIFFRACTION;

EID: 39649099134     PISSN: 00325910     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.powtec.2007.07.011     Document Type: Article

References (24)

1. Nagaya H., Satoh H., Kubo K., and Maki Y. Possible mechanism for the inhibition of gastric (H1,K1)-adenosine triphosphatase by the proton pump inhibitor AG-1749. J. Pharmacol. Exp. Ther. 248 (1989) 799-805
2. Baradell L.B., Faulds D., and McTavish D. Lansoprazole-a review of its pharmacodynamic and pharmacokinetics properties and its therapeutic efficacy in acid-related disorders. Drugs 44 (1992) 225-250
3. Spencer C.M., and Faults D. Lansoprazole-a reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs 48 (1994) 404-430
4. Gerloff J., Mignot A., Barth H., and Heintze K. Pharmacokinetics and absolute bioavailability of lansoprazole. Eur. J. Clin. Pharmacol. 50 (1996) 293-297
5. Landes B.D., Cournot A., and Vermerie N. The effect of food and antacids on lansoprazole absorption and distribution. Eur. J. Drug Metab. Pharmacokinet. 3 (1991) 315-320
6. Sohn D.R., Kwon J.T., Kim H.K., and Ishizaki T. Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4′-hydroxylation phenotype status. Clin. Pharmacol. Ther. 61 (1997) 574-582
7. Pearce R.E., Rodringues A.D., Goldstein J.A., and Parkinson A. Identification of the human P450 enzymes involved in lansoprazole metabolism. J. Pharmacol. Exp. Ther. 277 (1996) 805-816
8. Ito Y., Arai H., Uchino K., Iwasaki K., Shibata N., and Takada K. Effect of adsorbents on the absorption of lansoprazole with surfactant. Int. J. Pharm. 289 (2005) 69-77
9. Chen Y., Zhang G.G., Neilly J., Marsh K., Mawhinney D., and Sanzgiri Y.D. Enhancing the bioavailability of ABT-963 using solid dispersion containing Pluronic F-68. Int. J. Pharm. 286 (2004) 69-80
10. Law D., Wang W., Schmitt E.A., Qiu Y., Krill S.L., and Fort J.J. Properties of rapidly dissolving eutectic mixtures of poly(ethylene glycol) and fenofibrate: the eutectic microstructure. J. Pharm. Sci. 92 (2003) 505-515
11. Chiou W.L., and Riegelman S. Preparation and dissolution characteristics of several fast-release solid dispersions of griseofulvin. J. Pharm. Sci. 58 (1969) 1505-1510
12. Sethia S., and Squillante E. Solid dispersion of carbamazepine in PVP K30 by conventional solvent evaporation and supercritical methods. Int. J. Pharm. 272 (2004) 1-10
13. DellaGreca M., Iesce M.R., Previtera L., Rubino M., Temussi F., and Brigante M. Degradation of lansoprazole and omeprazole in the aquatic environment. Chemosphere 63 (2006) 1087-1093
14. Sun N., Wei X., Wu B., Chen J., Lu Y., and Wu W. Enhanced dissolution of silymarin/polyvinylpyrrolidone solid dispersion pellets prepared by a one-step fluid-bed coating technique. Powd. Tech 179 (2007) 196-204
15. van Drooge D.J., Hinrichs W.L., Visser M.R., and Frijlink H.W. Characterization of the molecular distribution of drugs in glassy solid dispersions at the nano-meter scale, using differential scanning calorimetry and gravimetric water vapour sorption techniques. Int. J. Pharm. 310 (2006) 220-229
16. Leuner C., and Dressman J. Improving drug solubility for oral delivery using solid dispersions. Eur. J. Pharm. Biopharm. 50 (2000) 47-60
17. Dugger H.A., Carlson J.D., Henderson W., Erdmann G.R., Alam S.M., and Dham R. Quamruzaman, Bioequivalence evaluation of lansoprazole 30-mg capsules (Lanfast and Lanzor) in healthy volunteers. Eur. J. Pharm. Biopharm. 51 (2001) 153-157
18. Karavas E., Ktistis G., Xenakis A., and Georgarakis E. Effect of hydrogen bonding interactions on the release mechanism of felodipine from nanodispersions with polyvinylpyrrolidone. Eur. J. Pharm. Biopharm. 63 (2006) 103-114
19. Kim E.J., Chun M.K., Jang J.S., Lee I.H., Lee K.R., and Choi H.K. Preparation of a solid dispersion of felodipine using a solvent wetting method. Eur. J. Pharm. Biopharm. 64 (2006) 200-205
20. Doherty C., and York P. Mechanisms of dissolution of frusemide/PVP solid dispersion. Int. J. Pharm. 34 (1987) 197-205
21. Beckett S.T., Francesconi M.G., Geary P.M., Mackenzie G., and Maulny A.P. DSC study of sucrose melting. Carbohydr. Res. 341 (2006) 2591-2599
22. Matrumoto T., and Zografi G. Physical properties of solid molecular dispersions of indomethacin with poly(vinylpyrrolidone) and poly(vinylpyrrolidone-co-vinyl-acetate) in relation to indomethacin crystallization. Pharm. Res. 16 (1999) 1722-1728
23. Van den Mooter G., Wuyts M., Blaton N., Busson R., Grobet P., Augustijns P., and Kinget R. Physical stabilisation of amorphous ketoconazole in solid dispersions with polyvinylpyrrolidone K25. Eur. J. Pharm. Sci. 12 (2001) 261-269
24. Tantishaiyakul V., and Kaewnopparat N. Properties of solid dispersions of piroxicam in polyvinylpyrrolidone. Int. J. Pharm. 181 (1999) 143-151